糖尿病前期与冠心病患者心脏死亡风险:ARTEMIS研究
ARTEMIS研究纳入接受血运重建和/或最佳药物治疗的冠心病患者,按口服葡萄糖耐量试验分为2型糖尿病、IGT、IFG及血糖正常组,比较心脏死亡风险。结果显示,糖尿病前期(IGT或IFG)患者的心脏死亡、MACE及全因死亡风险与血糖正常者无显著差异。
要点
- 冠心病合并糖尿病前期者的心脏死亡风险与血糖正常者无显著差异。
- IGT患者心脏死亡风险较2型糖尿病有降低趋势但未达统计学显著(P=0.069)。
- IFG患者全因死亡风险较2型糖尿病显著降低(P=0.015)。
核心结论
- 冠心病合并糖尿病前期(IGT或IFG)患者的心脏死亡率和MACE发生率与血糖正常者无显著差异。
研究设计与样本
- ARTEMIS研究为观察性研究,纳入接受血运重建(79%)、最佳药物治疗或两者兼有的冠心病患者。
- 按口服葡萄糖耐量试验结果分组:2型糖尿病834例、IGT 314例、IFG 103例、血糖正常697例。
- 主要终点为心脏死亡,次要终点为MACE(心脏死亡、心力衰竭或急性冠脉综合征)和全因死亡。
主要发现
- 平均随访6.3±1.6年期间,发生101例心脏死亡、385例MACE和208例死亡。
- IGT患者较2型糖尿病患者心脏死亡调整风险降低49%(P=0.069),全因死亡降低32%(P=0.076),MACE降低36%(P=0.011)。
- IFG患者较2型糖尿病患者全因死亡调整风险降低82%(P=0.015),心脏死亡与MACE风险两组无显著差异。
- IGT和IFG患者的心脏死亡、MACE及全因死亡调整风险与血糖正常者无显著差异。
临床怎么用
- 对冠心病合并糖尿病前期患者,其心脏死亡风险管理与血糖正常者相近,无需按糖尿病同等强度处理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare cardiac mortality in patients with CAD and prediabetes with that in CAD patients with normal glycemic status and type 2 diabetes. RESEARCH DESIGN AND METHODS: The Innovation to Reduce Cardiovascular Complications of Diabetes at the Intersection (ARTEMIS) study included patients with CAD after revascularization (79%), optimal medical therapy, or both. Patients had type 2 diabetes (n = 834), impaired glucose tolerance (IGT; n = 314), impaired fasting glucose (IFG; n = 103), or normal glycemic status (n = 697) as defined on the basis of the results of an oral glucose tolerance test. The primary end point was cardiac death. Major adverse cardiac event (MACE: cardiac death, heart failure, or acute coronary syndrome) and all-cause mortality were secondary end points. RESULTS: During a mean ± SD follow-up of 6.3 ± 1.6 years, 101 cardiac deaths, 385 MACEs, and 208 deaths occurred. Patients with IGT tended to have 49% lower adjusted risk for cardiac death (P = 0.069), 32% lower adjusted risk for all-cause mortality (P = 0.076), and 36% lower adjusted risk for MACE (P = 0.011) than patients with type 2 diabetes. The patients with IFG had 82% lower adjusted risk for all-cause mortality (P = 0.015) than the patients with type 2 diabetes, whereas risks for cardiac death and MACE did not differ significantly between the two groups. The adjusted risks for cardiac death, MACE, and all-cause mortality among patients with IGT and IFG did not significantly differ from those risks among patients with normal glycemic status. CONCLUSIONS: Cardiac mortality or incidence of MACE in patients with CAD with prediabetes (i.e., IGT or IFG after revascularization, optimal medical therapy, or both) does not differ from those values in patients with normal glycemic status.
引用
- Kiviniemi AM, Lepojärvi ES, Tulppo MP, et al. Prediabetes and Risk for Cardiac Death Among Patients With Coronary Artery Disease: The ARTEMIS Study. Diabetes Care. 2019. PMID: 31076416. doi:10.2337/dc18-2549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。